Technical Analysis for ONC - Oncolytics Biotech Inc.

Grade Last Price % Change Price Change
D 1.540 -3.14% -0.050
ONC closed down 3.14 percent on Friday, April 12, 2024, on 64 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 3
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.14%
Pocket Pivot Bullish Swing Setup -3.14%
Outside Day Range Expansion -3.14%
Gapped Down Weakness -3.14%
180 Bullish Setup Bullish Swing Setup -1.91%
Upper Bollinger Band Walk Strength -1.91%

   Recent Intraday Alerts

Alert Time
Possible Inside Day 1 day ago
Possible NR7 1 day ago
Down 5% 1 day ago
Fell Below 10 DMA 1 day ago
10 DMA Support 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oncolytics Biotech Inc. Description

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Health Medicine Clinic Cancer RTT Therapy Clinical Trial Oncology Lung Cancer Blastoma Chemotherapy Non Small Cell Lung Cancer Glioblastoma

Is ONC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.49
52 Week Low 1.2
Average Volume 94,838
200-Day Moving Average 2.283
50-Day Moving Average 1.441
20-Day Moving Average 1.460
10-Day Moving Average 1.529
Average True Range 0.092
RSI (14) 56.52
ADX 24.81
+DI 23.708
-DI 12.271
Chandelier Exit (Long, 3 ATRs) 1.474
Chandelier Exit (Short, 3 ATRs) 1.596
Upper Bollinger Bands 1.626
Lower Bollinger Band 1.294
Percent B (%b) 0.74
BandWidth 22.702
MACD Line 0.038
MACD Signal Line 0.021
MACD Histogram 0.0164
Fundamentals Value
Market Cap 66.68 Million
Num Shares 43.3 Million
EPS -1.02
Price-to-Earnings (P/E) Ratio -1.52
Price-to-Sales 0.00
Price-to-Book 7.41
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.645
Resistance 3 (R3) 1.643 1.607 1.628
Resistance 2 (R2) 1.607 1.580 1.608 1.622
Resistance 1 (R1) 1.573 1.563 1.555 1.575 1.616
Pivot Point 1.537 1.537 1.528 1.538 1.537
Support 1 (S1) 1.503 1.510 1.485 1.505 1.464
Support 2 (S2) 1.467 1.493 1.468 1.458
Support 3 (S3) 1.433 1.467 1.453
Support 4 (S4) 1.435